Marek Kwiatkowski
Corporate Officer/Principal chez QUIAPEG PHARMACEUTICALS HOLDING AB
Postes actifs de Marek Kwiatkowski
Sociétés | Poste | Début | Fin |
---|---|---|---|
QUIAPEG PHARMACEUTICALS HOLDING AB | Corporate Officer/Principal | 01/01/2022 | - |
Directeur Technique/Scientifique/R&D | 01/01/2017 | 01/01/2022 | |
University of Uppsala | Corporate Officer/Principal | - | - |
Otradama & Partners AB | Directeur/Membre du Conseil | - | - |
Historique de carrière de Marek Kwiatkowski
Anciens postes connus de Marek Kwiatkowski
Sociétés | Poste | Début | Fin |
---|---|---|---|
Quiatech AB
Quiatech AB Pharmaceuticals: MajorHealth Technology Quiatech AB develops and manufactures drugs. It is a research based company that develops enabling technologies for genetic analysis, molecular diagnostics, and gene-based therapeutics in the expanding market of DNA technologies that offer significant improvements in the quality of DNA microarray and other DNA oligonucleotide data. It has also developed a new modified RNA chemistry (Qt RNA Technology) utilizing a novel 2 protecting group on the RNA amidites, this development greatly improves the synthesis conditions, producing fully functional RNA at high yields. It is headquartered in Uppsala, Sweden. | Directeur/Membre du Conseil | - | 30/08/2007 |
Directeur Technique/Scientifique/R&D | - | 30/08/2007 | |
QuiaPEG Pharmaceuticals AB
QuiaPEG Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology QuiaPEG Pharmaceuticals AB operates as biotech company developing biopharmaceuticals based on a proprietary PEGylation technology platform. The firm’s technology is applicable on proteins, peptides, and small molecules. It develops novel long-acting biopharmaceuticals for the treatment of metabolic disorders. The company was founded by Hans Marcus Bosson in 2012 and is headquartered in Solna, Sweden. | Directeur/Membre du Conseil | 01/01/2012 | - |
Fondateur | 01/01/2012 | - | |
OLIGOvation AB
OLIGOvation AB Miscellaneous Commercial ServicesCommercial Services OLIGOvation AB develops enabling technologies for genetic analysis, molecular diagnostics and gene-based therapeutics. It offers services in the market of DNA technologies that offer improvements in the quality of DNA microarray and other DNA oligonucleotide data. The company was founded in February, 2000 and is headquartered in Uppsala, Sweden. | Directeur/Membre du Conseil | - | - |
Directeur Technique/Scientifique/R&D | - | - |
Formation de Marek Kwiatkowski
University of Uppsala | Doctorate Degree |
Uniwersytet Jagiellonski | Undergraduate Degree |
Statistiques
Internationale
Suède | 7 |
Pologne | 2 |
Opérationnelle
Director/Board Member | 4 |
Chief Tech/Sci/R&D Officer | 3 |
Corporate Officer/Principal | 2 |
Sectorielle
Health Technology | 4 |
Consumer Services | 3 |
Commercial Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
QUIAPEG PHARMACEUTICALS HOLDING AB | Health Technology |
Entreprise privées | 4 |
---|---|
Quiatech AB
Quiatech AB Pharmaceuticals: MajorHealth Technology Quiatech AB develops and manufactures drugs. It is a research based company that develops enabling technologies for genetic analysis, molecular diagnostics, and gene-based therapeutics in the expanding market of DNA technologies that offer significant improvements in the quality of DNA microarray and other DNA oligonucleotide data. It has also developed a new modified RNA chemistry (Qt RNA Technology) utilizing a novel 2 protecting group on the RNA amidites, this development greatly improves the synthesis conditions, producing fully functional RNA at high yields. It is headquartered in Uppsala, Sweden. | Health Technology |
OLIGOvation AB
OLIGOvation AB Miscellaneous Commercial ServicesCommercial Services OLIGOvation AB develops enabling technologies for genetic analysis, molecular diagnostics and gene-based therapeutics. It offers services in the market of DNA technologies that offer improvements in the quality of DNA microarray and other DNA oligonucleotide data. The company was founded in February, 2000 and is headquartered in Uppsala, Sweden. | Commercial Services |
QuiaPEG Pharmaceuticals AB
QuiaPEG Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology QuiaPEG Pharmaceuticals AB operates as biotech company developing biopharmaceuticals based on a proprietary PEGylation technology platform. The firm’s technology is applicable on proteins, peptides, and small molecules. It develops novel long-acting biopharmaceuticals for the treatment of metabolic disorders. The company was founded by Hans Marcus Bosson in 2012 and is headquartered in Solna, Sweden. | Health Technology |
Otradama & Partners AB |
- Bourse
- Insiders
- Marek Kwiatkowski
- Expérience